Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Elizabeth Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and Associate Chair for Research in the Department of Surgery at Brigham and Women's Hospital. She is also the Director of the Breast Immuno-Oncology program and Co-Director of the Breast Cancer Clinical Research Program at Dana-Farber Brigham Cancer Center. Dr. Mittendorf received her medical degree from Case Western Reserve University School of Medicine where she also completed a residency in General Surgery. She then served on active duty in the United States military before completing a fellowship in Surgical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Mittendorf also holds a PhD in Immunology from the University of Texas Graduate School of Biomedical Sciences at Houston. She is board certified by the American Board of Surgery. Dr. Mittendorf focuses her clinical and laboratory efforts on the study of breast cancer with a specific interest in immunotherapy. She has been the principle on a number of clinical protocols including the phase III PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study, and a multicenter phase II trial investigating the efficacy of CD8+ T cell eliciting vaccine in combination with trastuzumab which is based on preclinical data generated in her laboratory and follows a phase I trial she conducted demonstrating the combination to be safe. This trial is supported by a Breakthrough Award from the Department of Defense. She was recently awarded a prestigious Stand Up to Cancer award to support the conduct of a multicenter trial evaluating the combination of ipatasertib and atezolizumab in triple negative breast cancer. This trial is also informed by work from her laboratory showing transcriptional regulation of PD-L1 expression through the PI3K/AKT pathway. The current focus of her laboratory work is to determine the impact of standard and experimental therapies on immunologic aspects of the tumor microenvironment in order to inform rational trials of immunotherapeutic agents in breast cancer. She is also investigating novel targets for vaccine strategies. In addition to her work evaluating breast tumor immunology and immunotherapy, Dr. Mittendorf published extensively on a multitude of subjects related to breast cancer and surgical management of the disease to include incorporation of biologic factors into staging, management of the axilla, and surgery following receipt of neoadjuvant chemotherapy.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions